|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0169 USD | +0.93% |
|
-.--% | +3.68% |
| 05-27 | Acrux licenses Lenzetto for Australian market for A$5.4 million | RE |
| 05-27 | Hungary's Richter and Acrux agree to license transdermal estradiol spray for Australia | RE |
| Market Cap | 6.16M 4.31M 3.78M 3.49M 3.21M 6.06M 416M 41.77M 16.37M 203M 16.19M 15.84M 701M | P/E 2024 |
-3.44x | P/E 2025 | -0.95x |
|---|---|---|---|---|---|
| Enterprise Value | 8.93M 6.25M 5.48M 5.07M 4.66M 8.79M 603M 60.57M 23.74M 295M 23.48M 22.96M 1.02B | EV / Sales 2024 |
4.09x | EV / Sales 2025 | 7.81x |
| Free-Float |
78.27% | Yield 2024 * |
-
| Yield 2025 | - |
| 22-05-22 | Acrux : Application for quotation of securities - ACR | PU |
| 22-04-13 | Acrux : Application for quotation of securities - ACR | PU |
| 22-03-15 | Acrux : Application for quotation of securities - ACR | PU |
| 22-02-24 | Acrux : Updated Board Charter | PU |
| 22-02-24 | Acrux : Application for quotation of securities - ACR | PU |
| 1 day | +0.93% | ||
| 3 months | +275.56% | ||
| 6 months | +275.56% | ||
| Current year | +3.68% |
| Current year | 0 | 0.02 | |
| 1 year | 0 | 0.05 | |
| 3 years | 0 | 0.06 | |
| 5 years | 0 | 0.1 | |
| 10 years | 0 | 0.28 |
| Manager | Title | Age | Since |
|---|---|---|---|
John Warmbrunn
CEO | Chief Executive Officer | - | 2025-05-31 |
Joanna Johnson
DFI | Director of Finance/CFO | - | 2021-06-20 |
| Chief Tech/Sci/R&D Officer | - | 2015-02-14 |
| Director | Title | Age | Since |
|---|---|---|---|
Ross Dobinson
CHM | Chairman | 74 | 2005-12-31 |
Timothy Oldham
BRD | Director/Board Member | - | 2013-09-30 |
Geoff Brooke
BRD | Director/Board Member | 70 | 2016-05-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +0.93% | -.--% | - | - | 4.3M | ||
| +1.23% | +1.82% | +15.52% | +78.24% | 48.15B | ||
| +0.50% | +0.50% | +69.27% | +110.57% | 35.59B | ||
| +1.61% | +1.04% | -2.75% | +36.44% | 11.9B | ||
| +0.46% | +1.56% | +17.85% | +86.06% | 11.85B | ||
| -0.37% | +0.94% | +34.42% | +136.73% | 9.31B | ||
| -0.39% | -0.68% | +52.77% | -5.53% | 7.02B | ||
| -0.42% | +0.25% | +16.96% | +34.73% | 6.91B | ||
| -.--% | +0.14% | - | - | 6.79B | ||
| +0.18% | -2.69% | +0.63% | +202.37% | 6.55B | ||
| Average | +0.37% | -0.65% | +25.58% | +84.95% | 16.01B | |
| Weighted average by Cap. | +0.65% | -0.70% | +30.62% | +87.09% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 5.09M 3.56M 3.12M 2.89M 2.66M 5.01M 344M 34.53M 13.53M 168M 13.38M 13.09M 579M | 1.19M 833K 730K 675K 621K 1.17M 80.33M 8.07M 3.16M 39.3M 3.13M 3.06M 135M |
| Net income | -5.8M -4.06M -3.56M -3.29M -3.03M -5.71M -392M -39.33M -15.42M -192M -15.25M -14.91M -660M | -5.94M -4.16M -3.65M -3.37M -3.1M -5.85M -401M -40.32M -15.8M -196M -15.63M -15.29M -677M |
| Net Debt | 759K 531K 466K 430K 396K 747K 51.24M 5.15M 2.02M 25.07M 2M 1.95M 86.37M | 2.77M 1.94M 1.7M 1.57M 1.45M 2.73M 187M 18.8M 7.37M 91.56M 7.29M 7.13M 315M |
Employees
43
Sector
Pharmaceuticals
Annual profits - Rate of surprise
- Stock Market
- Stocks
- ACR Stock
- ARUXF Stock
Select your edition
All financial news and data tailored to specific country editions
















